Want to see TNGX full AI Analyst Report?
Top Page
Tango Therapeutics
(NASDAQ:TNGX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$24.00
▼(-3.11% Downside)
Action:Reiterated
Date:10/24/26
The score is primarily held back by weak financial performance—large ongoing losses and substantial cash burn—despite a relatively solid balance sheet with low leverage. Technicals are moderately supportive but appear near-term overbought, and valuation is constrained by negative earnings and no dividend yield. A notable positive corporate event (strong combination-data readout and plans for a registrational trial) provides an upside catalyst but does not fully offset current profitability and funding risks.
Positive Factors
Low Leverage
Modest leverage reduces near-term balance-sheet pressure and leaves more flexibility to fund clinical development. Compared with a heavily indebted biotechnology model, limited debt exposure lowers refinancing and interest burdens, although operating losses still require careful capital planning.
Negative Factors
Heavy Cash Burn
Substantial and consistently negative cash flow means Tango must continue financing research and development externally while products remain in development. Persistent burn reduces financial flexibility and makes future access to capital important for sustaining clinical progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Modest leverage reduces near-term balance-sheet pressure and leaves more flexibility to fund clinical development. Compared with a heavily indebted biotechnology model, limited debt exposure lowers refinancing and interest burdens, although operating losses still require careful capital planning.
Read all positive factors
Tango Therapeutics (TNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.74B
Dividend YieldN/A
Average Volume (3M)4.14M
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth121.47%
EPS Growth36.95%
CountryUS
Employees137
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding168,610,370
10 Day Avg. Volume5,443,905
30 Day Avg. Volume4,138,669
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)2.97
Price to Sales (P/S)16.50
P/FCF Ratio-7.36
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue68.82
Enterprise Value/Gross Profit70.04
Enterprise Value/Ebitda-30.39
Forecast
1Y Price Target
$44.14Price Target Upside78.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Tango Therapeutics Business Overview & Revenue Model
Company Description
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine meth...
Tango Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.81M | 62.38M | 42.07M | 36.53M | 24.86M | 37.04M |
| Gross Profit | 52.87M | 60.10M | 42.07M | 36.53M | 24.86M | 37.04M |
| EBITDA | -121.86M | -99.31M | -127.59M | -99.19M | -106.51M | -57.05M |
| Net Income | -123.72M | -101.59M | -130.30M | -101.74M | -108.18M | -58.23M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 398.69M | 316.49M | 402.57M | 436.47M | 500.15M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01B | 343.14M | 257.92M | 336.88M | 366.13M | 485.25M |
| Total Debt | 31.99M | 33.57M | 36.49M | 38.92M | 41.13M | 1.50M |
| Total Liabilities | 49.35M | 52.51M | 116.97M | 149.46M | 186.99M | 155.41M |
| Stockholders Equity | 1.02B | 346.18M | 199.52M | 253.11M | 249.48M | 344.75M |
Cash Flow | ||||||
| Free Cash Flow | -144.27M | -139.93M | -132.25M | -119.51M | -116.77M | -61.36M |
| Operating Cash Flow | -143.90M | -138.89M | -131.50M | -117.98M | -109.08M | -59.53M |
| Investing Cash Flow | -524.58M | -40.87M | 86.13M | 41.43M | 26.40M | -183.43M |
| Financing Cash Flow | 974.33M | 222.50M | 47.66M | 82.41M | 1.61M | 357.32M |
Tango Therapeutics Technical Analysis
Negative
24.77
Price Trends
23.79
Negative
26.20
Negative
22.10
Positive
Market Momentum
0.11
Negative
44.39
Neutral
45.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Negative. The current price of 24.77 is above the 20-day moving average (MA) of 23.64, above the 50-day MA of 23.79, and above the 200-day MA of 22.10, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 44.39 is Neutral, neither overbought nor oversold. The STOCH value of 45.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TNGX.
Tango Therapeutics Risk Analysis
Tango Therapeutics disclosed 78 risk factors in its most recent earnings report. Tango Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tango Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $3.74B | -26.11 | -25.74% | ― | 121.47% | 36.95% | |
56 Neutral | $5.98B | -36.57 | -20.76% | 64.52% | ― | 32.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.07B | -4.02 | -47.04% | ― | -65.40% | -164.71% | |
47 Neutral | $654.77M | -3.28 | -188.27% | 6.80% | -17.90% | 32.10% | |
46 Neutral | $150.62M | -0.95 | -48.40% | ― | 15.98% | -40.75% | |
45 Neutral | $389.83M | -1.80 | -256.67% | ― | 4.08% | -343.67% |
* Healthcare Sector Average
TNGX
Tango Therapeutics
22.20
14.43
185.65%
ORKA
Oruka Therapeutics
90.33
62.63
226.10%
IMTX
Immatics
7.15
-3.43
-32.42%
SPRY
ARS Pharmaceuticals
3.92
-5.64
-59.00%
PRME
Prime Medicine, Inc.
3.61
-1.54
-29.90%
UPB
Upstream Bio, Inc.
2.75
-20.83
-88.34%
Tango Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Tango Therapeutics Highlights Positive Vopimetostat Combination Data
Positive
Oct 23, 2026
On October 23, 2026, Tango Therapeutics reported updated Phase 1/2 data showing that vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors delivered strong efficacy and manageable safety in MTAP-deleted, RAS-mutant pancreatic a...
Private Placements and FinancingRegulatory Filings and Compliance
Tango Therapeutics Expands At-The-Market Equity Program
Neutral
Aug 11, 2026
On November 21, 2025, Tango Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC for an at-the-market equity offering of up to $100 million in common stock, registered on a shelf registration statement. As of August 11, 2026...
Business Operations and StrategyExecutive/Board Changes
Tango Therapeutics Announces Executive Chair Barbara Weber’s Departure
Neutral
Aug 6, 2026
Tango Therapeutics disclosed that Dr. Barbara Weber’s employment as Executive Chair ended on August 3, 2026, in line with her amended employment agreement, and that she simultaneously resigned from all officer and board positions without any...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.